IRIS

Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)

CASRN 2691-41-0 | DTXSID3024237

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (11 pp, 107 K) Last Updated: 09/26/1988

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic 5 x 10-2 Hepatic lesions NOAEL : 5.0 x 101
mg/kg-day
1000 Low

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (11 pp, 107 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (11 pp, 107 K) Last Updated: 03/01/1989

WOE Characterization Framework for WOE Characterization
D (Not classifiable as to human carcinogenicity) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • No cancer bioassays or epidemiological studies are available.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (11 pp, 107 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (11 pp, 107 K)

Not assessed under the IRIS Program.

Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.